Arena announced encouraging data from a small Phase IIa study for oloranib (APD371) in abdominal pain associated with Crohn’s disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.
On A Roll: Arena Continues Streak Of Positive Data With Small Crohn’s Pain Study
By Michael Tattory|
2018-09-28T11:36:13-04:00
September 28th, 2018|News|Comments Off on On A Roll: Arena Continues Streak Of Positive Data With Small Crohn’s Pain Study